Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.

MLA

Osman, Abdullah A., et al. “Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 29, no. 7, Apr. 2023, pp. 1344–59. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-22-2747.

APA

Osman, A. A., Arslan, E., Bartels, M., Michikawa, C., Lindemann, A., Tomczak, K., Yu, W., Sandulache, V., Ma, W., Shen, L., Wang, J., Singh, A. K., Frederick, M. J., Spencer, N. D., Kovacs, J., Heffernan, T., Symmans, W. F., Rai, K., & Myers, J. N. (2023). Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 29(7), 1344–1359. https://doi.org/10.1158/1078-0432.CCR-22-2747

Chicago

Osman, Abdullah A, Emre Arslan, Mason Bartels, Chieko Michikawa, Antje Lindemann, Katarzyna Tomczak, Wangjie Yu, et al. 2023. “Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 29 (7): 1344–59. doi:10.1158/1078-0432.CCR-22-2747.